2.91

0.69% -0.02

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $2.91, with a volume of 110.31K. It is down -0.69% in the last 24 hours and up +61.24% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$2.89

Open:

$2.84

24h Volume:

110.31K

Relative Volume:

0.04

Market Cap:

$621.44M

Revenue:

$12.87M

Net Income/Loss:

$-114.34M

P/E Ratio:

-3.3657

EPS:

-0.8646

Net Cash Flow:

$-79.23M

1W Performance:

+12.11%

1M Performance:

+61.24%

6M Performance:

+16.19%

1Y Performance:

-3.37%

1-Day Range:

$2.81

$2.905

1-Week Range:

$2.555

$3.24

52-Week Range:

$1.05

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1176)

Industry

Biotechnology (668)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	2.895	508.75M	12.87M	-114.34M	-79.23M	-0.8646
ONC Beigene Ltd Adr	239.25	23.78B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	434.80	108.15B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.24	43.44M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.08	61.69B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	74.87	5.72B	0	-153.72M	-103.81M	-2.00

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

02:55 AM

FY2025 EPS Estimates for TSHA Lifted by Cantor Fitzgerald - Defense World

02:55 AM

May 21, 2025

Taysha, FDA agree on next steps of REVEAL trial for Rett gene therapy - Rett Syndrome News

May 21, 2025

May 19, 2025

Taysha outlines expedited pivotal trial start for TSHA-102 following FDA alignment - MSN

May 19, 2025

May 18, 2025

Canaccord Genuity Group Forecasts Strong Price Appreciation for Taysha Gene Therapies (NASDAQ:TSHA) Stock - Defense World

May 18, 2025

May 17, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.1% Following Analyst Upgrade - Defense World

May 17, 2025

May 16, 2025